NASDAQ:OMED - Oncomed Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$0.8005 +0.01 (+1.27 %)
(As of 12/16/2018 01:35 PM ET)
Previous Close$0.8005
Today's Range$0.7301 - $0.8660
52-Week Range$0.73 - $4.20
Volume1.70 million shs
Average Volume414,769 shs
Market Capitalization$30.92 million
P/E Ratio5.00
Dividend YieldN/A
Beta1.95

Headlines

Oncomed Pharmaceuticals (NASDAQ OMED) News Headlines

Source:
DateHeadline
Oncomed Pharmaceuticals (OMED) Receives Market Perform Rating from Wells Fargo & CoOncomed Pharmaceuticals (OMED) Receives Market Perform Rating from Wells Fargo & Co
www.americanbankingnews.com - December 6 at 1:15 PM
Oncomed Pharmaceuticals Inc (OMED) Receives Consensus Recommendation of "Hold" from BrokeragesOncomed Pharmaceuticals Inc (OMED) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 6 at 12:47 PM
This Peninsula biotech foresaw deals worth $3 billion. Now its lining up a $57 million mergerThis Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger
www.bizjournals.com - December 6 at 9:50 AM
Mereo BioPharma To Acquire US Oncology Firm In All Stock DealMereo BioPharma To Acquire US Oncology Firm In All Stock Deal
www.morningstar.co.uk - December 5 at 10:03 AM
Oncomed Pharmaceuticals Inc (OMED) Expected to Post Quarterly Sales of $7.91 MillionOncomed Pharmaceuticals Inc (OMED) Expected to Post Quarterly Sales of $7.91 Million
www.americanbankingnews.com - November 29 at 4:49 AM
 Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) Will Announce Earnings of -$0.22 Per Share Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - November 27 at 9:46 AM
Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and ...Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and ...
globenewswire.com - November 17 at 9:43 AM
OncoMed Pharma (OMED) Reports Early Clinical Data for Anti-TIGIT AntibodyOncoMed Pharma (OMED) Reports Early Clinical Data for Anti-TIGIT Antibody
www.streetinsider.com - November 9 at 4:08 PM
OncoMed Announces Early Clinical Data for anti-TIGIT AntibodyOncoMed Announces Early Clinical Data for anti-TIGIT Antibody
finance.yahoo.com - November 9 at 10:13 AM
OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Delivered A Weaker ROE Than Its IndustryOncoMed Pharmaceuticals Inc (NASDAQ:OMED) Delivered A Weaker ROE Than Its Industry
finance.yahoo.com - November 5 at 4:18 PM
OncoMed Announces Third Quarter 2018 Financial Results and Operational HighlightsOncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights
finance.yahoo.com - November 2 at 10:37 AM
OncoMed: 3Q Earnings SnapshotOncoMed: 3Q Earnings Snapshot
finance.yahoo.com - November 2 at 10:37 AM
OncoMed Pharmaceuticals (OMED) Q3 Earnings Preview: How Are Events Shaping Up?OncoMed Pharmaceuticals (OMED) Q3 Earnings Preview: How Are Events Shaping Up?
www.zacks.com - October 26 at 10:09 AM
OncoMed Pharma (OMED) Reports Interim Phase 1b Results for Navicixizumab & Paclitaxel Combination Therapy in ...OncoMed Pharma (OMED) Reports Interim Phase 1b Results for Navicixizumab & Paclitaxel Combination Therapy in ...
www.streetinsider.com - October 23 at 9:55 AM
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum ...OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum ...
globenewswire.com - October 21 at 4:02 PM
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian CancerOncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
finance.yahoo.com - October 20 at 9:24 AM
OncoMed Pharma (OMED) says Celgene notified it of decision not to exercise option to license rosmantuzumabOncoMed Pharma (OMED) says Celgene notified it of decision not to exercise option to license rosmantuzumab
www.streetinsider.com - October 19 at 10:04 AM
OncoMed Pharma down 8% after hours on Celgene withdrawal from rosmantuzumabOncoMed Pharma down 8% after hours on Celgene withdrawal from rosmantuzumab
seekingalpha.com - October 18 at 9:57 AM
OncoMed up 25% on positive early-stage navicixizumab dataOncoMed up 25% on positive early-stage navicixizumab data
seekingalpha.com - October 17 at 3:55 PM
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of ...OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of ...
globenewswire.com - October 11 at 3:53 PM
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology MeetingOncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting
finance.yahoo.com - October 9 at 9:29 AM
OncoMed Announces Publication of Phase 1a Data of NavicixizumabOncoMed Announces Publication of Phase 1a Data of Navicixizumab
finance.yahoo.com - September 24 at 9:58 AM
Celgene backs away from OncoMeds navicixizumabCelgene backs away from OncoMed's navicixizumab
seekingalpha.com - September 20 at 10:26 AM
OncoMed Provides Update on Navicixizumab PartnershipOncoMed Provides Update on Navicixizumab Partnership
finance.yahoo.com - September 20 at 10:26 AM
Can OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improve Your Portfolio Returns?Can OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improve Your Portfolio Returns?
finance.yahoo.com - September 12 at 4:01 PM
OncoMed to Present at Two Upcoming Investor Conferences in SeptemberOncoMed to Present at Two Upcoming Investor Conferences in September
finance.yahoo.com - August 29 at 4:11 PM
OncoMed Pharmaceuticals (OMED) Reports Q2 Loss, Misses Revenue EstimatesOncoMed Pharmaceuticals (OMED) Reports Q2 Loss, Misses Revenue Estimates
www.zacks.com - August 2 at 10:40 AM
BRIEF-Oncomed Pharmaceuticals Q2 Loss Per Share $0.10BRIEF-Oncomed Pharmaceuticals Q2 Loss Per Share $0.10
www.msn.com - August 2 at 10:40 AM
OncoMed: 2Q Earnings SnapshotOncoMed: 2Q Earnings Snapshot
finance.yahoo.com - August 2 at 10:40 AM
OncoMed Announces Second Quarter 2018 Financial Results and Operational HighlightsOncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights
finance.yahoo.com - August 2 at 10:40 AM
OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical TrialOncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial
finance.yahoo.com - June 12 at 9:46 AM
OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial  OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial  
finance.yahoo.com - June 12 at 9:46 AM
OncoMed Announces First Quarter 2018 Financial Results and Operational HighlightsOncoMed Announces First Quarter 2018 Financial Results and Operational Highlights
finance.yahoo.com - May 9 at 9:54 AM
OncoMed: 1Q Earnings SnapshotOncoMed: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:54 AM
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/YAcorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
finance.yahoo.com - May 3 at 4:05 PM
OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018
finance.yahoo.com - May 1 at 9:50 AM
Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/YAllergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y
finance.yahoo.com - April 30 at 4:07 PM
OncoMed Pharma (OMED) Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at AACROncoMed Pharma (OMED) Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at AACR
www.streetinsider.com - April 19 at 10:07 AM
OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual MeetingOncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 18 at 10:06 AM
OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual MeetingOncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 9 at 10:21 AM
Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?
finance.yahoo.com - March 27 at 4:11 PM
BRIEF-OncoMed Announces Appointment Of John Lewicki As CEOBRIEF-OncoMed Announces Appointment Of John Lewicki As CEO
www.reuters.com - March 19 at 4:14 PM
OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of DirectorsOncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors
finance.yahoo.com - March 19 at 10:36 AM
OncoMed Pharmaceuticals Inc (NASDAQ:OMED): What Are The Future Prospects?OncoMed Pharmaceuticals Inc (NASDAQ:OMED): What Are The Future Prospects?
finance.yahoo.com - March 16 at 4:13 PM
Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy NowCatalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
finance.yahoo.com - March 14 at 4:08 PM
OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational HighlightsOncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
finance.yahoo.com - March 9 at 11:54 AM
OncoMed tops Street 4Q forecastsOncoMed tops Street 4Q forecasts
finance.yahoo.com - March 9 at 11:54 AM
When Can We Expect A Profit From OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?When Can We Expect A Profit From OncoMed Pharmaceuticals Inc (NASDAQ:OMED)?
finance.yahoo.com - March 9 at 11:54 AM
OncoMed Pharmaceuticals Q4 Earnings PreviewOncoMed Pharmaceuticals Q4 Earnings Preview
finance.yahoo.com - March 8 at 4:12 PM
Has OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improved Earnings Growth In Recent Times?Has OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 7 at 4:04 PM
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel